- Home
- GNTA vs TVRD Comparison
GNTA vs TVRD Comparison
Compare GNTA & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | TVRD |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 37.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNTA | TVRD |
|---|---|---|
| Price | $1.01 | $3.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 3.0M | 96.2K |
| Earning Date | 03-24-2026 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $3.74 |
| 52 Week High | $10.00 | $43.65 |
Technical Indicators
Market Signals| Indicator | GNTA | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 31.60 | 37.98 |
| Support Level | $1.26 | $4.39 |
| Resistance Level | $1.70 | $4.89 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 1.22 | 12.38 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.